Our LEADERSHIP

guides the organization

OUR BOARD

of Directors

NancyS

Nancy Stagliano, PhD

Executive Chair

Adam Rosenthal, PhD

CEO and Co-founder

Beth Seidenberg, MD

Director

Carl Gordon, PhD, CFA

Director

VijayL

Vijay Lathi

Board Observer

Amrit Nagpal

Board Observer

NANCY STAGLIANO PHD

Executive Chair

Nancy is CEO and Chair of the Board of Neuron23, Inc., a South San Francisco–based precision neurology and immunology therapeutics company. An experienced CEO, Nancy has led True North Therapeutics (acquired by Bioverativ in 2017), iPierian (acquired by BMS in 2014), and CytomX Therapeutics (CTMX). With more than 20 years of experience in the biotechnology industry, Nancy’s career path has always stayed close to the science, beginning with 7+ years at Millennium Pharmaceuticals in Cambridge, MA, in the discovery organization.

Nancy is Chair of the Board of Latigo Bio, a Thousand Oaks–based biotech focused on non-opioid pain medicines. Nancy also serves as a director on the not-for-profit board of PanCAN, the Pancreatic Cancer Action Network. In the past, Nancy has also advised venture capital firms Westlake Village BioPartners and New Leaf Ventures.

Nancy has a PhD in Neuroscience from the University of Miami School of Medicine, an MS in Biomedical Engineering, and a BS in Electrical Engineering, both from Drexel University.

X

Adam Rosenthal PHD

CEO and Co-founder

Adam is CEO and co-founder of Electra Therapeutics. He brings previous operating experience across multiple biotech companies focused on rare diseases, and broad expertise in company building, fundraising, business development, and strategic planning.
 
Previously, Adam served as Chief Business Officer at True North Therapeutics, where he raised more than $140M in private financings and contributed to the company’s acquisition by Bioverativ for $825M. His experience also includes serving as Vice President, Head of Corporate Development at iPierian, which was acquired by BMS for $725M, and being a Project Leader at the Boston Consulting Group.
 
Adam earned BS degrees in Electrical Engineering and Brain and Cognitive Science, and an MEng degree in Electrical Engineering and Computer Science, all at Massachusetts Institute of Technology, as well as a PhD in Biomedical Engineering at the Massachusetts Institute of Technology and Harvard.
X

BETH SEIDENBERG MD

Director

Beth is a longtime life sciences investor, applying her broad medical expertise to the venture capital world, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients.

As a founding managing director of Westlake Village BioPartners, general partner at Kleiner Perkins, and numerous other endeavors, Seidenberg has incubated and invested in more than 40 biotech ventures since 2005. Among many others, they include ARMO Biosciences, Arresto Biosciences, Arsenal Biosciences, Atara Biotherapeutics, Cell Design Labs, Epizyme, Flexus Biosciences, iPierian, Kyverna Therapeutics, Livongo Health, Neuron23, Progyny, RAPT Therapeutics, Tesaro, Tmunity Therapeutics, and True North Therapeutics.

Beth’s impact has been recognized across the industry. She was awarded the 2022 Healthcare Businesswomen’s Association “Woman of the Year” Award and was recently named by Barron’s as one of the 100 most influential women in US finance. She was also recognized in the 2020 Forbes Midas List as a top tech investor.

In addition to her time in life science investing, Beth has significant senior-level industry experience, with leadership roles at Amgen, Bristol-Myers Squibb, and Merck Research Laboratories.

Beth holds an MD from the University of Miami Leonard M. Miller School of Medicine and a BS from Barnard College. She conducted her post-graduate training at The National Institutes of Health and Johns Hopkins University School of Medicine.

X

CARL GORDON PHD, CFA

Director

Carl is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. He currently serves on the boards of directors of several public and private companies.

Carl received a BA in Chemistry from Harvard College and a PhD in Molecular Biology from the Massachusetts Institute of Technology, and he was a Fellow at The Rockefeller University.

X

Vijay Lathi

Board Observer

Vijay is a Founder and Managing Director of New Leaf Venture Partners, a leading healthcare-focused venture capital firm that over the past 15 years has invested over a billion dollars across 126 companies, developing drugs and technologies to revolutionize the diagnosis, treatment, and delivery of care. Vijay’s investment activity has spanned all areas of healthcare technology, including the development and execution of the firm’s strategy around convergent information technologies. Example investments include ePocrates (sold to Athena Health), LabCyte (sold to Thermo Fischer), CareDx (CDNA), iRhythm (IRTC), Oxford Immunotec (sold to Perkin Elmer), Ilypsa (sold to Amgen), and Relypsa (sold to Gallenica).

Vijay graduated from the Massachusetts Institute of Technology and Stanford University, where he received his BS and MS in Chemical Engineering.

X

AMRIT NAGPAL

Board Observer

Amrit is a Partner and Managing Director at Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York. Prior to Redmile Group, he worked as an analyst and portfolio manager at Weintraub Capital Management, and before that at Robertson Stephens, a San Francisco–based investment bank.

Amrit holds a BA in Economics from Columbia University and an MBA from UCLA Anderson School of Management.

X

Demo

Board Observer

demo

X

OUR

Investors

OrbiMed
Redmile Group
Cormorant Asset Management
Cowen
RA CAPITAL
New Leaf Venture Partners
STAR